Ruxolitinib is an oral inhibitor of JAK1 and JAK2, which is approved for the treatment of myeloproliferative neoplasm-associated myelofibrosis, further myeloproliferative neoplasms, polycythemia vera and refractory cancer.
Documents
DMF
基本文件流程错误SQL调试用户
请求信息 : 2025-04-02 13:27:23 HTTP/1.1 GET : https://senovatech.com/anti_cancer/223.html